Metagenomi, Inc. Common Stock (MGX)
MGX Stock Price Chart
Explore Metagenomi, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze MGX price movements and trends.
MGX Company Profile
Discover essential business fundamentals and corporate details for Metagenomi, Inc. Common Stock (MGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Apr 2006
Employees
202.00
Website
https://www.metagenomi.coCEO
Jian Irish
Description
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
MGX Financial Timeline
Browse a chronological timeline of Metagenomi, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.55, while revenue estimate is $3.01m.
Earnings released on 11 May 2026
EPS came in at -$0.61 falling short of the estimated -$0.60 by -1.67%, while revenue for the quarter reached $1.25m , missing expectations by -78.86%.
Earnings released on 5 Mar 2026
EPS came in at -$0.60 falling short of the estimated -$0.58 by -3.45%, while revenue for the quarter reached $3.91m , missing expectations by -46.64%.
Earnings released on 11 Nov 2025
EPS came in at -$0.55 surpassing the estimated -$0.60 by +8.33%, while revenue for the quarter reached $8.66m , beating expectations by +10.69%.
Earnings released on 12 Aug 2025
EPS came in at -$0.54 surpassing the estimated -$0.68 by +20.59%, while revenue for the quarter reached $8.51m , beating expectations by +7.22%.
Earnings released on 13 May 2025
EPS came in at -$0.68 falling short of the estimated -$0.62 by -9.68%, while revenue for the quarter reached $4.13m , missing expectations by -50.28%.
Earnings released on 17 Mar 2025
EPS came in at -$0.63 falling short of the estimated -$0.62 by -1.61%, while revenue for the quarter reached $9.61m , beating expectations by +4.15%.
Earnings released on 13 Nov 2024
EPS came in at -$0.45 surpassing the estimated -$0.70 by +35.71%, while revenue for the quarter reached $11.51m , beating expectations by +70.35%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.59 by +50.85%, while revenue for the quarter reached $20.01m , beating expectations by +58.17%.
Earnings released on 14 May 2024
EPS came in at -$1.19 falling short of the estimated -$0.95 by -25.26%, while revenue for the quarter reached $11.16m , beating expectations by +42.02%.
Earnings released on 10 Feb 2024
EPS came in at -$0.51 surpassing the estimated -$2.04 by +74.76%, while revenue for the quarter reached $12.40m , beating expectations by +6.89%.
Earnings released on 30 Sept 2023
EPS came in at -$0.53 , while revenue for the quarter reached $12.36m .
Earnings released on 30 Jun 2023
EPS came in at -$0.35 , while revenue for the quarter reached $11.34m .
Earnings released on 31 Mar 2023
EPS came in at -$0.54 , while revenue for the quarter reached $8.66m .
Earnings released on 31 Dec 2022
EPS came in at -$0.39 , while revenue for the quarter reached $5.60m .
Earnings released on 29 Sept 2022
EPS came in at -$0.28 , while revenue for the quarter reached $4.91m .
Earnings released on 30 Jun 2022
EPS came in at -$1.57 , while revenue for the quarter reached $3.35m .
Earnings released on 31 Mar 2022
EPS came in at -$1.57 , while revenue for the quarter reached $3.35m .
MGX Stock Performance
Access detailed MGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
